Histone Deacetylase Inhibitors in Cancer Therapy

Factors related to neutropenic events in early stage breast cancer patients

(2017) E. Culakova et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy

(2017) P. N. Munster et al.   JOURNAL OF CLINICAL ONCOLOGY

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

(2017) R. G. Bociek et al.   JOURNAL OF CLINICAL ONCOLOGY

HDACs and HDAC inhibitors in colon cancer

(2010) John M. Mariadason   Epigenetics

Current status of epigenetic treatment in myelodysplastic syndromes

(2008) Andrea Kuendgen et al.   ANNALS OF HEMATOLOGY

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells

(2008) R. Rao et al.   BLOOD

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells

(2008) W. Fiskus et al.   BLOOD

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation

(2008) A. Rodriguez-Gonzalez et al.   CANCER RESEARCH

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

(2008) D. S. Schrump et al.   CLINICAL CANCER RESEARCH

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

(2008) V. M. Klimek et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in lymphoma and solid malignancies

(2008) Walid Rasheed et al.   Expert Review of Anticancer Therapy

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2008) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells

(2008) Marielle Dejligbjerg et al.   Molecular Cancer

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model

(2008) A. Miyanaga et al.   MOLECULAR CANCER THERAPEUTICS

Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16

(2007) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY